Karl-Erik Andersson, M.D., Ph.D.Wake Forest School of Medicine

Karl-Erik Andersson, M.D., Ph.D.


Contact Information

Academic: 336-713-1195 | Department: 336-716-2011


Education & Training

  • M.D., Lund University Fac Med-Sweden, 1968
Karl-Erik Andersson, M.D., Ph.D.

Karl-Erik Andersson, M.D., Ph.D.

Professor, Institute for Regenerative Medicine
Physiology & Pharmacology

Contact Information

Academic: 336-713-1195 | Department: 336-716-2011


Recent Publications

Melatonin improves erectile function in rats with chronic lower body ischemia. Sawada N, Nomiya M, Zarifpour M, Mitsui T, Takeda M, Andersson KE.. J Sex Med. 2016;13(2):179-186.

Potential future pharmacological treatment of bladder dysfunction. Andersson KE.. Basic Clin Pharmacol Toxicol. 2016;():.

The Clock mutant mouse is a novel experimental model for nocturia and nocturnal polyuria. Ihara T, Mitsui T, Nakamura Y, Kira S, Miyamoto T, Nakagomi H, Sawada N, Hirayama Y, Shibata K, Shigetomi E, Shinozaki Y, Yoshiyama M, Andersson KE, Nakao A, Takeda M, Koizumi S.. Neurourol Urodyn. 2016;():.

Cell vs. chemokine therapy in a nonhuman primate model of chronic intrinsic urinary sphincter deficiency. Williams JK, Dean A, Badra S, Lankford S, Poppante K, Badlani G, Andersson KE.. J Urol. 2016;():.

Regenerative medicine therapies for stress urinary incontinence. Williams JK, Dean A, Badlani G, Andersson KE.. J Urol. 2016;():.

Re: Nonantimuscarinic treatment for overactive bladder: a systematic review [editorial]. Andersson KE.. Eur Urol. 2016;():.

Intraprostatic injections for lower urinary tract symptoms treatment. Andersson KE.. Curr Opin Urol. 2015;25(1):12-18.

Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia. Zarifpour M, Nomiya M, Sawada N, Andersson KE.. Prostate. 2015;75(3):233-241.

Mechanisms of ATP release - future therapeutic targets? [editorial]. Andersson KE.. BJU Int. 2015;115(6):850-851.

Potential of stem cell treatment in detrusor dysfunction. Andersson KE.. Adv Drug Deliv Rev. 2015;82-83():117-122.

Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms. Nomiya M, Andersson KE, Yamaguchi O.. Int J Urol. 2015;22(1):40-46.

Chronic pelvic ischemia: contribution to the pathogenesis of lower urinary tract symptoms (LUTS): a new target for pharmacological treatment?. Andersson KE, Nomiya M, Yamaguchi O.. Low Urin Tract Symptoms. 2015;7(1):1-8.

Urinary bladder mucosal responses to ischemia. Sunagawa M, Wolf-Johnston A, Nomiya M, Sawada N, Andersson KE, Hisamitsu T, Birder LA.. World J Urol. 2015;33(2):275-280.

Superoxide overproduction and kidney fibrosis: a new animal model. Guimaraes-Souza NK, Yamaleyeva LM, Lu B, Ramos AC, Bishop CE, Andersson KE.. Einstein (Sao Paulo). 2015;13(1):79-88.

Alpha1 -adrenergic receptors mediate bladder overactivity induced by cold stress in rats with bladder outlet obstruction. Yamagishi T, Ishizuka O, Imamura T, Yokoyama H, Ogawa T, Kurizaki Y, Nishizawa O, Andersson KE.. Neurourol Urodyn. 2015;34(3):280-285.

Serotonin (5-HT)2A/2C receptor agonist (2,5-dimethoxy-4-idophenyl)-2-aminopropane hydrochloride (DOI) improves voiding efficiency in the diabetic rat. Tu H, Cao N, Gu B, Si J, Chen Z, Andersson KE.. BJU Int. 2015;116(1):147-155.

Drug therapy of overactive bladder - what is coming next?. Andersson KE.. Korean J Urol. 2015;56(10):673-679.

The potential utility of non-invasive imaging to monitor restoration of bladder structure and function following subtotal cystectomy (STC). Burmeister D, Bishwokarma B, AbouShwareb T, Olson J, Herco M, Tan J, Andersson KE, Christ G.. BMC Urol. 2015;15(1):103.

Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor. Fullhase C, Hennenberg M, Sandner P, Strittmatter F, Niedworok C, Bauer RM, Gratzke C, Soler R, Stief C, Andersson KE.. Neurourol Urodyn. 2015;34(8):787-793.

Translational research and functional changes in voiding function in older adults. Kullmann FA, Birder LA, Andersson KE.. Clin Geriatr Med. 2015;31(4):535-548.

Differentiated adipose-derived stem cells for bladder bioengineering. Salemi S, Tremp M, Plock JA, Andersson KE, Gobet R, Sulser T, Eberli D.. Scand J Urol. 2015;49(5):407-414.

What's going on the the overactive bladder arena?. Andersson KE.. Drugs Future. 2015;40(12):827-834.

Lamina propria: the functional center of the bladder?. Andersson KE, McCloskey KD.. Neurourol Urodyn. 2014;33(1):9-16.

Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome. Chapple CR, Abrams P, Andersson KE, Radziszewski P, Masuda T, Small M, Kuwayama T, Deacon S.. J Urol. 2014;191(1):253-260.

Functional consequences of chronic bladder ischemia. Yamaguchi O, Nomiya M, Andersson KE.. Neurourol Urodyn. 2014;33(1):54-58.

Bladder function in a cannabinoid receptor type 1 knockout mouse. Fullhase C, Campeau L, Sibaev A, Storr M, Hennenberg M, Gratzke C, Stief C, Hedlund P, Andersson KE.. BJU Int. 2014;113(1):144-151.

Bladder underactivity [editorial]. Andersson KE.. Eur Urol. 2014;65(2):399-401.

Effects of allogeneic bone marrow derived mesenchymal stromal cell therapy on voiding function in a rat model of Parkinson disease. Campeau L, Soler R, Sittadjody S, Pareta R, Nomiya M, Zarifpour M, Opara EC, Yoo JJ, Andersson KE.. J Urol. 2014;191(3):850-859.

An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, Novara G, Chapple C.. Eur Urol. 2014;65(5):981-990.

Characterization of functional bladder regeneration in mice [abstract]. Zarifpour M, Sandberg J, Abolbashari M, Vadhavkar M, Kelkar S, Mohs A, Marini F, Andersson KE, Christ G.. Neurourol Urodyn. 2014;33(2):186.

Terminology, epidemiology, etiology, and pathophysiology of nocturia. Van Kerrebroeck P, Andersson KE.. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5.

Characterization of bladder function in a cannabinoid receptor type 2 knockout mouse in vivo and in vitro. Campeau L, Fullhase C, Sawada N, Gratzke C, Hedlund P, Howlett AC, Andersson KE.. Neurourol Urodyn. 2014;33(5):566-570.

Correlation of gene expression with bladder capacity in interstitial cystitis/bladder pain syndrome. Colaco M, Koslov DS, Keys T, Evans RJ, Badlani GH, Andersson KE, Walker SJ.. J Urol. 2014;192(4):1123-1129.

Downregulation of metabolic activity increases cell survival under hypoxic conditions: potential applications for tissue engineering. Kim J, Andersson KE, Jackson JD, Lee SJ, Atala A, Yoo JJ.. Tissue Eng Part A. 2014;20(15-16):2265-2272.

Progressive vascular damage may lead to bladder underactivity in rats. Nomiya M, Yamaguchi O, Akaihata H, Hata J, Sawada N, Kojima Y, Andersson KE.. J Urol. 2014;191(5):1462-1469.

The many faces of impaired bladder emptying. Andersson KE.. Curr Opin Urol. 2014;24(4):363-369.

Current and future drugs for treatment of MS-associated bladder dysfunction. Andersson KE.. Ann Phys Rehabil Med. 2014;57(5):321-328.

Pathophysiology of idiopathic overactive bladder and the success of treatment: a systematic review from ICI-RS 2013. Hanna-Mitchell AT, Kashyap M, Chan WV, Andersson KE, Tannenbaum C.. Neurourol Urodyn. 2014;33(5):611-617.

Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate. Kunit T, Gratzke C, Schreiber A, Strittmatter F, Waidelich R, Rutz B, Loidl W, Andersson KE, Stief CG, Hennenberg M.. Am J Physiol Renal Physiol. 2014;307(7):F823-F832.

The use of pharmacotherapy for male patients with urgency and stress incontinence. Andersson KE.. Curr Opin Urol. 2014;24(6):571-577.

A comparison of cellular and acellular (chemokine) therapy in a primate model of urinary sphincter deficiency [abstract]. Williams JK, Andersson K.. Neurourol Urodyn. 2014;33(6):835-836.

Calcium signalling in Cajal-like interstitial cells of the lower urinary tract. Drumm BT, Koh SD, Andersson KE, Ward SM.. Nat Rev Urol. 2014;11(10):555-564.

Induction and maintenance of cellular hypometabolsm for improved tissue survival for reconstructive procedures [abstract]. Jackson JR, Kim N, Kim J, Andersson KE, Yoo J, Atala A.. J Am Coll Surg. 2014;219(3 Suppl):S142.

Adipose-derived stem cells (ADSCs) and muscle precursor cells (MPCs) for the treatment of bladder voiding dysfunction. Tremp M, Salemi S, Largo R, Andersson KE, A Plock J, Aboushwareb T, Sulser T, Eberli D.. World J Urol. 2014;32(5):1241-1248.

The effect of the 5-HT7 serotonin receptor agonist, LP44, on micturition in rats with chronic spinal cord injury. Gang W, Hongjian T, Jasheng C, Jiemin S, Zhong C, Yuemin X, Baojun G, Andersson KE.. Neurourol Urodyn. 2014;33(7):1165-1170.

Effects of chronic pelvic ischemia on bladder function [abstract]. Andersson KE.. Acta Physiol (Oxf). 2014;211(Suppl 696):52-53.

Transcriptome analysis of bladder biopsy from interstitial cystitis/bladder pain syndrome patients. Walker SJ, Colaco M, Koslov DS, Keys T, Evans RJ, Badlani GH, Andersson KE.. Genom Data. 2014;2():366-368.

Alpha-blockers and antimuscarinics for male lower urinary tract symptoms: the search goes on [editorial]. Gratzke C, Andersson K-E.. Eur Urol. 2013;63(1):166-167.

Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. Hood B, Andersson K-E.. Int J Urol. 2013;20(1):21-27.

Male lower urinary tract symptoms and alpha1D-adrenoceptors. Ishizuka O, Imamura T, Kurizaki Y, Nishizawa O, Andersson KE.. Int J Urol. 2013;20(1):73-78.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Karl-Erik Andersson, M.D., Ph.D.

Karl-Erik Andersson, M.D., Ph.D.

Professor, Institute for Regenerative Medicine
Physiology & Pharmacology

Quick Reference

Request an Appointment
New Patients


Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.